Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease

Cholesterol guidelines typically prioritize primary prevention statin therapy on the basis of 10-year risk of cardiovascular disease. The advent of generic pricing may justify expansion of statin eligibility. Moreover, 10-year risk may not be the optimal approach for statin prioritization. We estima...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli-Lynch, Ciaran N., Lewsey, James, Boyd, Kathleen A., French, Dustin D., Jordan, Neil, Moran, Andrew E., Sattar, Naveed, Preiss, David, Briggs, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022692/
https://www.ncbi.nlm.nih.gov/pubmed/35249370
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022692/
https://www.ncbi.nlm.nih.gov/pubmed/35249370
http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057631

Ejemplares similares